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Abstract
A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal cancers with a high frequency of
DNA hypermethylation in a specific group of CpG islands. Recent studies have shown that an activating mutation of BRAF
(BRAF
V600E) is tightly associated with CIMP, raising the question of whether BRAF
V600E plays a causal role in the development
of CIMP or whether CIMP provides a favorable environment for the acquisition of BRAF
V600E. We employed Illumina
GoldenGate DNA methylation technology, which interrogates 1,505 CpG sites in 807 different genes, to further study this
association. We first examined whether expression of BRAF
V600E causes DNA hypermethylation by stably expressing
BRAF
V600E in the CIMP-negative, BRAF wild-type COLO 320DM colorectal cancer cell line. We determined 100 CIMP-
associated CpG sites and examined changes in DNA methylation in eight stably transfected clones over multiple passages.
We found that BRAF
V600E is not sufficient to induce CIMP in our system. Secondly, considering the alternative possibility, we
identified genes whose DNA hypermethylation was closely linked to BRAF
V600E and CIMP in 235 primary colorectal tumors.
Interestingly, genes that showed the most significant link include those that mediate various signaling pathways implicated
in colorectal tumorigenesis, such as BMP3 and BMP6 (BMP signaling), EPHA3, KIT, and FLT1 (receptor tyrosine kinases) and
SMO (Hedgehog signaling). Furthermore, we identified CIMP-dependent DNA hypermethylation of IGFBP7, which has been
shown to mediate BRAF
V600E-induced cellular senescence and apoptosis. Promoter DNA hypermethylation of IGFBP7 was
associated with silencing of the gene. CIMP-specific inactivation of BRAF
V600E-induced senescence and apoptosis pathways
by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAF
V600E in CIMP+ colorectal
cancer. Our data will be useful for future investigations toward understanding CIMP in colorectal cancer and gaining
insights into the role of aberrant DNA hypermethylation in colorectal tumorigenesis.
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Introduction
Aberrant DNA methylation at CpG islands has been widely
observed in cancer. Promoter CpG island hypermethylation
associated with inactivation of selected tumor suppressor genes
appears to be critical in tumors from inception through to
maintenance of the tumor phenotype [1]. Distinct subgroups of
several types of human cancers have been proposed to have a CpG
island methylator phenotype (CIMP) in which an exceptionally
high frequency of cancer-specific DNA hypermethylation is found
[2,3]. Although this concept has been controversial [4], we have
confirmed the existence of CIMP in colorectal cancer in a large-
scale comprehensive study [5].
CIMP in colorectal cancer may arise through a distinct pathway
originating in certain subtypes of serrated polyps [6] and is
observed in approximately 15% of all colorectal cancer cases [5,7].
Features associated with CIMP in colorectal cancer include gender
(female), proximal location, and poorly differentiated or mucinous
histology [3,5,7,8]. Our study using a newly developed CIMP
marker panel in colorectal cancers demonstrated that sporadic
microsatellite instability (MSI+) occurs as a consequence of CIMP-
associated MLH1 DNA hypermethylation [5]. Furthermore, we
found a strong association of CIMP with the presence of an
activated mutant form of BRAF (BRAF
V600E) [5]. Both CIMP and
BRAF mutations have been reported in the earliest stages of
colorectal neoplasia: CIMP in apparently normal mucosa of
patients predisposed to multiple serrated polyps [9] and BRAF
mutations in aberrant crypt foci [10].
The RAS-RAF-MEK-ERK signaling pathway is frequently
hyperactivated in colorectal cancer. KRAS mutations occur most
frequently in 30–40% of all colorectal cancers [11] and BRAF
mutations are present at a frequency of 5–22%, in which the
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V600E variant accounts for ,90% of
all the BRAF mutations [12]. Mutations in KRAS and BRAF are
generally mutually exclusive, implying equivalent downstream
effects in tumorigenesis [13]. However, recent studies have
indicated that mutations of these genes might play distinct roles
in tumor initiation and/or maintenance [10,14].
The extremely tight association between BRAF
V600E and CIMP
raises the question of whether BRAF
V600E plays a causal role in
the development of CIMP or whether CIMP-associated promoter
hypermethylation provides a favorable setting for the acquisition
of BRAF
V600E. In this study, we searched for possible molecular
explanations for the association between BRAF
V600E and CIMP
using the Illumina GoldenGate DNA methylation platform, which
examines the DNA methylation status of 1,505 CpG sites located
at 807 genes. The GoldenGate DNA methylation assay has been
widely used in various studies and is now a standard method for
DNA methylation analysis [15–24]. Findings obtained from the
commercially available ‘‘GoldenGate Methylation Cancer Panel
I’’, in particular, have been validated using various other
techniques [15–17,22,23], making it a reliable source for DNA
methylation measurements across 1,505 loci. We were not able to
demonstrate a causal contribution of BRAF
V600E to CIMP in our
cell culture system. However, we identified genes whose DNA
hypermethylation was significantly linked with BRAF
V600E in
primary colorectal tumors. Inactivation of these specific genes in
the context of CIMP might drive the acquisition of BRAF
V600E in
CIMP+ colorectal tumors.
Results
Characterization of 21 Human Colorectal Cancer Cell
Lines
We first sought to determine whether expression of BRAF
V600E
would induce DNA hypermethylation at CpG sites associated with
CIMP in an in vitro cell culture system. Since primary colonic
epithelial cells were not readily available, we screened for colorectal
cancer cell lines that do not have substantial DNA methylation at
CIMP-defining loci and carry wild-type forms of both BRAF and
KRAS. Such cell lines would serve as suitable systems for the
introduction of BRAF
V600E. We selected 21 colorectal cancer cell
lines, characterized their DNA methylation profiles, and deter-
mined their BRAF and KRAS mutation status (Figure 1). We used
Figure 1. Characteristics of 21 colorectal cancer cell lines. MethyLight was used to assess the DNA methylation status of five CIMP-defining
markers. A PMR of $10 was used as a threshold for positive methylation. Black boxes indicate PMR $10, and white boxes indicate PMR ,10. The DNA
methylation frequencies of the five CIMP markers increase from top to bottom. Microsatellite instability status for each cell line is listed as
microsatellite stable (MSS) or harboring instability (MSI). The mutation status of BRAF exon 15 and KRAS exon 2 are listed.
doi:10.1371/journal.pone.0008357.g001
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defining markers previously identified in our laboratory [5]. Using a
PMR (percent of methylated reference) of $10 as a threshold for
positive methylation, we identified six cell lines that lacked DNA
methylation for all five CIMP-specific markers (Figure 1). To test
our hypothesis, we initially chose the BRAF and KRAS wild-type
Caco-2 and COLO 320DM cell lines for their ease in culturing and
transfection. However, the study described below is limited to
COLO 320DM cells, since we were not able to isolate any stably
transfected Caco-2 clones that showed detectable level of
BRAF
V600E expression (data not shown).
Stable Transfection of BRAF
V600E in COLO 320DM Cells
We transfected COLO 320DM cells with an HA-tagged
BRAF
V600E cDNA and isolated G418-resistant clones. The
expression level of BRAF
V600E was determined by western blotting
using an antibody against the HA epitope (Figure 2A). The activity
of BRAF
V600E was confirmed by examining the activation of
ERK1/2 using an antibody against phosphorylated ERK1/2
(Figure 2A). Eight stably transfected clones exhibiting high
expression of BRAF
V600E, as well as strong activation of ERK1/
2, were individually grown in culture, and genomic DNA was
isolated at various passages (between 2 and 27) from these clones.
Four empty-vector transfected clones (EVCs) were grown in the
same conditions and used as controls.
DNA Methylation Analysis of the BRAF
V600E Transfected
COLO 320DM Clones
We next determined the DNA methylation status of 1,505 CpG
sites located at 807 different genes in each of the eight BRAF
V600E
clones and four EVCs using the Illumina GoldenGate Methylation
Cancer Panel 1 platform (Figure 2B). We found that the DNA
methylation b-values across all 1,505 CpG sites in the BRAF
V600E
transfected clones (regardless of their BRAF
V600E expression level)
were very similar to those of empty-vector control clones and
relatively stable over time. This suggests that there was no overall
increase in DNA hypermethylation in BRAF
V600E transfected
clones in the CpG targets analyzed (Figure 2B).
Figure 2. Selection of BRAF
V600E stably-transfected clones and their Illumina GoldenGate DNA methylation profiles. (A) Expression of
BRAF
V600E and ERK1/2 phosphorylation in stably transfected COLO 320DM cells. Blots were probed with the anti-HA antibodies for HA-BRAF
V600E, anti-
phospho-ERK1/2, and anti-ERK1. Asterisks indicate the eight BRAF
V600E transfected clones that were subjected to DNA methylation analysis at various
cell passages. (B) DNA methylation profiles of untransfected COLO 320DM cells, empty vector and BRAF
V600E transfected COLO 320DM clones, as
determined by the Illumina GoldenGate DNA methylation assay. The DNA methylation data were scored as b-values as previously defined [16]. Each
row corresponds to an individual CpG locus and the data were sorted by average b-value across all samples. Each clone is ordered from left to right in
increasing number of passages. EVC: empty-vector transfected clones.
doi:10.1371/journal.pone.0008357.g002
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BRAF
V600E specifically increased the DNA methylation of only
CIMP-associated markers in the 1,505 interrogated CpG sites.
These sites were determined by screening 58 primary colorectal
tumor samples using the Illumina GoldenGate DNA methylation
platform (Dataset S1). The mutation status of BRAF and KRAS in
these samples had been determined previously [5] (Table S1).
Unsupervised two-dimensional cluster analysis of the DNA
methylation b-values revealed a distinct cluster of 11 tumor
samples, the majority of which contained BRAF
V600E and showed
frequent DNA methylation of known CIMP-associated markers,
including CDKN2A, IGF2, and MLH1 (data not shown). We
defined this subgroup as CIMP-positive tumors (Figure 3). We
then identified a total of 100 CpG sites that have significantly
higher levels of DNA methylation in CIMP-positive (CIMP+)
versus CIMP-negative (CIMP2) tumors (P,0.001 after correction
for multiple comparisons, see the Materials and Methods section)
(Table S2). It should be noted that reactions for three of the
MethyLight-based CIMP markers (CACNA1G, NEUROG1, and
SOCS1) previously identified in our laboratory are not included in
the Illumina GoldenGate Methylation Cancer Panel 1 platform.
The RUNX3 Illumina GoldenGate reactions did not demonstrate
CIMP-specific behavior. One possible explanation for this
discrepancy could be that these reactions are designed around
the transcription start site of RUNX3 isoform 1, whereas our
CIMP-specific RUNX3 MethyLight reaction is designed at the
promoter CpG island of the RUNX3 isoform 2 [5]. We saw no
apparent difference in DNA methylation between BRAF
V600E
transfected clones and EVCs at these CIMP-associated CpG sites
(Figure 3). Interestingly, we observed that the mean DNA
methylation b-value of the 100 CIMP-specific loci increased as a
function of cell passage (Figure 4A and 4B). However, this increase
did not correlate with the levels of BRAF
V600E expression and was
also observed in cells transfected with the control vector
(Figure 4B). This general increase in the mean b-value is specific
for CIMP-associated loci, since the mean b-value from several sets
of 100 randomly selected CpG sites did not show a similar trend
(Figure 4C and 4D). Therefore, we concluded that, although
CIMP-associated CpG islands may be prone to acquire DNA
methylation in certain culture conditions, BRAF
V600E does not
specifically induce CIMP in COLO 320DM cells.
Identification of Genes That Are Significantly Methylated
in Colorectal Tumors Harboring BRAF
V600E
We also considered the alternative hypothesis that promoter
methylation of specific gene targets provides a favorable setting for
Figure 3. Illumina GoldenGate DNA methylation profiles of CIMP-associated loci. CIMP+ tumors and the CIMP-associated loci in 58 primary
tumor samples were defined as described in the Materials and Methods section. Each row corresponds to an individual locus of the 100 locus panel,
and the data were sorted by the mean b-value of each locus over all 58 primary tumor samples. Each BRAF
V600E transfected clone and EVC is ordered
from left to right in increasing number of passages. Tumors with BRAF and KRAS mutations are indicated by a circle and a triangle, respectively. X:
mutation status is not available. Each BRAF
V600E transfected clone and EVC is ordered from left to right in increasing number of passages. ‘‘p’’
indicates the DNA methylation profiles of parent untransfected COLO 320DM cells.
doi:10.1371/journal.pone.0008357.g003
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We previously identified the CIMP status and BRAF mutation
status of 235 primary colorectal tumor samples [5]. We found
BRAF
V600E in 33 tumors (14.0%); 31 of these were classified as
CIMP+ and only 2 as CIMP2. We performed the Illumina
GoldenGate DNA methylation assay on these samples, and
identified 60 genes, represented by 89 CpG sites, that are
significantly methylated (P,0.001) in the 33 BRAF
V600E-positive
tumors (Table S3). These genes are candidates for CIMP-specific
inactivation, which may closely synergize with the BRAF
V600E to
promote tumorigenesis.
To validate the data generated using the GoldenGate DNA
methylation platform, we analyzed the DNA methylation status of
four CIMP-specific genes (CALCA, EPHA3, KIT, and SLC5A8)o na
subset of four CIMP-positive and 16 CIMP-negative tumors on
the Illumina Infinium DNA methylation platform. These four
genes were selected because both analytical platforms interrogate
the DNA methylation status of the identical CpG dinucleotide. We
then examined the concordance of DNA methylation at each of
these loci between the two platforms, and found a high correlation
coefficient in all cases (CALCA: 0.94, EPHA3: 0.95, KIT: 0.95,
SLC5A8: 0.86), lending further support to our initial GoldenGate-
based DNA methylation screen.
We confirmed the recently observed associations between DNA
hypermethylation of BMP3 and MCC with CIMP+ and BRAF
V600E
in colorectal cancer [25,26]. We also found CIMP-specific DNA
hypermethylation of BMP6. The simultaneous epigenetic inactiva-
tion of BMP3 and BMP6 was shown to be associated with the
activation of the RAS-RAF-MEK-ERK signaling pathway in non-
small-cell lung cancer [27]. Moreover, we found an association of
SLC5A8 and TIMP3 DNA methylation with BRAF
V600E in our
colorectal tumor samples, as had been previously reported in
papillary thyroid carcinomas [28]. The functional consequence of
DNA hypermethylation of such tumor suppressor genes linked with
CIMP+ and BRAF
V600E remains speculative [25–28].
Furthermore, we found that DNA methylation of SMO,a
component of Hedgehog (Hh) signaling, was tightly linked to
colorectal tumors with BRAF
V600E (Table S3). Intriguingly, it has
been recently reported that increased expression of SMO
contributes to colorectal tumorigenesis [29]. However, Arimura
et al. also showed that colorectal cancer cell lines harboring
BRAF
V600E, including COLO 205, HT-29 and RKO, did not
appear to show expression of SMO [29]. Our data indicates that
CIMP-specific promoter DNA hypermethylation might be
involved in the repression of SMO in colorectal tumors carrying
BRAF
V600E (Table S3).
Promoter DNA Hypermethylation and Transcriptional
Silencing of IGFBP7 in BRAF Mutant CIMP+ Colorectal
Cancer
We identified the IGFBP7 promoter CpG island as a target for
DNA methylation in colorectal tumors harboring BRAF
V600E (P
Figure 4. Changes in DNA methylation levels over passages in BRAF
V600E and EVC stably-transfected clones. Black lines indicate
BRAF
V600E expressing clones and gray lines represent empty-vector transfected control clones. Each graphing point represents mean b-values across
indicated CpG sites from the Illumina GoldenGate DNA methylation assay at various passages for each clone. (A) All 1,505 CpG loci from the Illumina
GoldenGate assay. (B) Only 100 CIMP-associated loci are profiled. (C) One hundred randomly chosen CpG loci. (D) One hundred non-CIMP loci, which
show mean b-values similar to the 100 CIMP-associated loci.
doi:10.1371/journal.pone.0008357.g004
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29, Odds ratio =12). BRAF
V600E has been shown
to induce cellular senescence [30–32]. Oncogene-induced senes-
cence (OIS) has been recognized as an important tumor suppressor
mechanism [33]. The underlying molecular mechanism of
BRAF
V600E-induced senescence and apoptosis has been elucidated
in a recent study [34]. It has been demonstrated that expression of
IGFBP7 is both necessary and sufficient to induce senescence and
apoptosis mediated by BRAF
V600E. Intriguingly, IGFBP7 was
shown to be epigenetically silenced by CpG island promoter
hypermethylation specifically in primary melanoma samples
carrying BRAF
V600E, indicating that loss of IGFBP7 expression is
critical in the development of BRAF
V600E-positive melanoma [34].
The Illumina GoldenGate Methylation Cancer Panel 1
platform contains two IGFBP7 probes (IGFBP7_P297_F and
IGFBP7_P371_F) that interrogate the DNA methylation status of
two distinct CpG dinucleotides in the IGFBP7 promoter CpG
island (Figure 5A). We found that these two CpG sites in the
IGFBP7 promoter are cancer-specifically methylated (Figure 5B)
and strongly associated with both BRAF
V600E (Wilcoxon rank-sum
test, P value =2.0610
210) and CIMP (P value =3.6610
29)
(Figure 5C). It has been reported that colorectal tumors with KRAS
mutations also show DNA hypermethylation at CIMP-associated
markers, albeit at a low frequency, and have high levels of DNA
methylation of genes that undergo age-associated DNA hyper-
methylation. These tumors have been described as CIMP-low or
CIMP2 [35,36]. We did not find an association between IGFBP7
DNA hypermethylation and KRAS mutations when we excluded
tumors with mutant BRAF (P value =0.85). In agreement with
Figure 5. IGFBP7 promoter DNA methylation in primary colorectal cancers. (A) Genomic map of IGFBP7 promoter-associated CpG island,
transcription start site (TSS) and exon 1 based on the UCSC genome browser (March 2006 assembly). The location of CpG sites interrogated by the
Illumina GoldenGate DNA methylation assay is indicated by vertical arrows. (B) DNA methylation levels of the two CpG dinucelotides in the IGFBP7
promoter CpG island. b-values of each CpG site in 10 tumors (five CIMP2 tumors with wild-type BRAF and five CIMP+ tumors with mutant BRAF, black
bars) and adjacent non-tumor tissues (gray bars) are listed. (C) IGFBP7 promoter DNA methylation box plots of 235 human colorectal tumors stratified
by BRAF mutation status (left) and CIMP+ status (right) at the IGFBP7 P371 locus. In the box plots, the ends of the box are the 25th and 75th quartiles.
The line within the box identifies the median b-value. The whiskers above and below the box extend to at most 1.5 times the IQR. The CIMP status of
each colorectal tumor sample is determined as described in the Materials and Methods section.
doi:10.1371/journal.pone.0008357.g005
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IGFBP7 is mostly present in colorectal cancer cell lines which
harbor BRAF
V600E and show frequent DNA methylation of the
five-gene CIMP-specific marker panel previously described
(Figure 6). Real-time RT-PCR analysis of colorectal cancer cell
lines showed that IGFBP7 mRNA expression was inversely related
to DNA hypermethylation, as cell lines with IGFBP7 hypermethy-
lation showed little or no IGFBP7 gene expression (Figure 6).
Among the CIMP2 cells we examined, only COLO 320DM
showed DNA hypermethylation of the IGFBP7 CpG island
promoter with minimal level of expression. In retrospect, this
unique characteristic of COLO 320DM cells compared to the
other CIMP2 cell lines might have enabled these cells to tolerate
mutant BRAF overexpression, and may explain our difficulties in
obtaining BRAF
V600E expressing clones in other colorectal cancer
cell line such as Caco-2.
Discussion
CIMP in colorectal cancer provides a unique opportunity to
study molecular mechanisms that lead to epigenetic changes in
cancer and the contributions of these changes in the development of
the disease [3,37]. The distinct features found in CIMP are
important clues in understanding this phenotype [3,5,7,8].
Particularly striking is the extremely tight association between
CIMP and BRAF
V600E [5]. Mechanisms linking epigenetic (CIMP)
and genetic (BRAF mutation) events and the temporal sequence in
which these two events take place have attracted interest [37].
In this study, by using the high-throughput Illumina Gold-
enGate DNA methylation platform, we investigated the link
between CIMP and BRAF
V600E in colorectal cancer. We first
tested whether expression of BRAF
V600E causes DNA hyper-
methylation by stably expressing BRAF
V600E in the CIMP-
negative, BRAF wild-type COLO 320DM colorectal cancer cell
line. We have examined DNA methylation changes in 100 CIMP-
associated CpG sites, and found that BRAF
V600E is not sufficient
to induce DNA hypermethylation at these sites. One caveat of our
system is that BRAF
V600E could play a role in inducing DNA
methylation only early in colorectal tumorigenesis, as BRAF
mutations have been described at the earliest stage of tumor
development [10,38,39]. It is possible that a unique set of genetic
and/or epigenetic changes that occurred in COLO 320DM cells
might have created an unfavorable environment for BRAF
V600E to
induce DNA hypermethylation. Experiments similar to those
described above using Caco-2 cells, which also show CIMP– and
carry BRAF-wild type, were not successful. We were not able to
obtain any stably transfected clones that exhibited detectable levels
of BRAF
V600E (data not shown). Sustained BRAF
V600E expression
might be incompatible with Caco-2 cell proliferation due to
cellular senescence or apoptosis induced by BRAF
V600E.I ti s
noteworthy that our RT-PCR analysis showed the robust
expression of IGFBP7, a mediator of BRAF
V600E-induced
senescence or apoptosis, in Caco-2 cells in contrast to COLO
320DM cells.
Previously, we described CIMP-associated methylation of
MLH1 as the underlying basis for mismatch repair deficiency
(MSI+) in sporadic colorectal cancer [5]. Minoo et al. reported
MLH1 DNA methylation upon stable transfection of BRAF
V600E
into the NCM460 cell line [40]. In our system, we did not detect
such an increase in MLH1 DNA methylation (data not shown).
Figure 6. Analysis of DNA methylation and mRNA expression of IGFBP7 in colorectal cancer cell lines. Quantitative real-time RT-PCR
analysis of IGFBP7 expression. IGFBP7 expression levels are presented relative to PCNA expression. The error bars indicate the standard deviation of
technical triplicate measurements. The number of methylated loci among the five CIMP markers and mutation status of BRAF and KRAS listed in
Figure 1 are provided.
doi:10.1371/journal.pone.0008357.g006
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V600E primary tumors we examined
only 42% (14/33) showed MLH1 DNA hypermethylation.
Therefore, BRAF
V600E may affect DNA hypermethylation of
MLH1 but only in certain circumstances. Interestingly, in the
proposed serrated pathway to CIMP+ tumors, both BRAF
mutations and CIMP+ have been observed in early precursor
lesions, whereas MSI+ has not [6,10,41]. Thus, inactivation of
MLH1 might occur at a later stage of tumor development. Minoo
and colleagues observed the DNA hypermethylation of CDKN2A
and 15 other CIMP-associated markers (IGFBP7 was not
examined) in parent NCM460 cells, which limited their ability
to study further the role of BRAF
V600E inducing CIMP in their
experimental system [40].
Intriguingly, we observed that the overall DNA methylation
level of the CIMP-specific loci in our stably transfected cells
increases as a function of cell passage. It is interesting to note that a
selection drug in cultured cells has been described to result in
changes in global chromatin structure [42], and a similar process
may be associated with our observations here.
In addition, we found relatively large inter-clonal (among
different clones) variation in DNA methylation levels in our
transfection experiments (Figures 2B and 3), with an average R
2
correlation calculated based on four EVCs of 0.8860.01 (6 s.d.).
Our average intra-clonal (within clones at different passages) R
2
correlation is 0.9760.01 and the R
2 correlation between technical
replicates in Illumina GoldenGate DNA methylation analysis is
0.9860.02 [16]. Consequently, we found some large differences in
DNA methylation at several loci even among control clones
(Figures 2B and 3). This emphasizes the importance of using
multiple clones for this type of studies.
Alternatively, the strong association between CIMP and
BRAF
V600E might arise if CIMP specifically provides a favorable
cellular context for BRAF
V600E to promote tumorigenesis. In the
second set of experiments, we determined genes whose DNA
hypermethylation was tightly linked to BRAF
V600E and CIMP+ in
colorectal cancer. Intriguingly, we observed CIMP-dependent
DNA hypermethylation and transcriptional inactivation of
IGFBP7, which has been shown to mediate BRAF
V600E-induced
cellular senescence and apoptosis [34]. BRAF
V600E has been
shown to induce cellular senescence in cultured and primary
human cells [30,31], as well as mouse model [32]. Oncogene-
induced senescence (OIS) has been recognized as an important
tumor suppressor mechanism [33]. In order for BRAF
V600E to
promote its oncogenic effects, additional cooperative events are
required to bypass senescence [33]. Recently, the molecular basis
of BRAF
V600E-induced senescence and apoptosis has been studied
in detail. Wajapeyee et al. identified IGFBP7 as a mediator of
BRAF
V600E-induced senescence in human primary fibroblasts
using a genome-wide shRNA screen. Their subsequent findings
suggest that IGFBP7 expression is both necessary and sufficient to
induce senescence and apoptosis in human primary melanocytes
and melanoma, respectively. Moreover, they observed loss of
IGFBP7 in primary BRAF
V600E-positive melanoma samples and
concluded that silencing of IGFBP7 expression is a critical step in
the development of a melanoma harboring BRAF
V600E [34].
Promoter-associated CpG island DNA hypermethylation of
IGFBP7 has been reported in human colorectal cancer cell lines as
well. The DNA methylation inhibitor 5-aza-29-deoxycytidine has
been shown to restore IGFBP7 expression in colorectal cancer cell
lines, indicating that the DNA hypermethylation plays a major
role in silencing of this gene in colorectal cancer [43]. However, its
association with BRAF mutation and CIMP+ status in human
colorectal cancers has not been explored. In this study, we found
that IGFBP7 DNA hypermethylation is tumor-specific and tightly
associated with colorectal tumors carrying BRAF
V600E and
exhibiting CIMP. Moreover, we found that IGFBP7 DNA
hypermethylation is associated with loss of expression in CIMP+
colorectal cancer cell lines. CIMP-specific inactivation of
BRAF
V600E-induced senescence and apoptosis pathway by
IGFBP7 DNA hypermethylation might create a favorable context
for the acquisition of BRAF
V600E in CIMP+ colorectal cancer.
Importantly, IGFBP7 DNA hypermethylation was not observed
in all of the BRAF mutant colorectal tumors. Lin et al. examined
the DNA sequence of the promoter and exonic regions of IGFBP7
in ten colorectal cancer cell lines. They did not find mutations
associated with inactivation of IGFBP7 in their cell lines [43].
However, an increasing number of genes have recently been
reported to be involved in OIS, and cooperation of multiple
different signals appears to be critical for OIS [44]. It is therefore
possible that CIMP-associated DNA hypermethylation events may
impair OIS by affecting other components of the OIS signaling
pathway in colorectal cancer.
Additional genes that showed CIMP-specific DNA hypermethy-
lation include those that mediate various signaling pathways
implicated in colorectal tumorigenesis (Table S3). The functional
consequence of CIMP-specific DNA hypermethylation of such
genes will be the subject of future investigations. We found that
both BMP3 and BMP6 are targeted for CIMP-specific DNA
hypermethylation and are strongly linked with BRAF
V600E.
Disruption of the BMP signaling pathway has been proposed to
play a role in colorectal tumorigenesis [25]. Concurrent epigenetic
inactivation of BMP3 and BMP6 was shown to be associated with
the hyperactivation of the RAS-RAF-MEK-ERK signaling
pathway in non-small-cell lung cancer [27]. Furthermore, receptor
tyrosine kinases (RTKs) such as EPHA3, KIT, and FLT1 also
showed CIMP-associated DNA hypermethylation (Table S3).
Somatic mutations or overexpression of these genes has been
implicated in colorectal tumorigenesis, which may involve the
activation of the RAS-RAF-MEK-ERK signaling [45–50]. The
potential inactivation of these genes in CIMP may lead to the
development of tumors dependent on oncogenic BRAF-driven
hyperactivation of the RAS-RAF-MEK-ERK signaling pathway.
Furthermore, we also found that DNA methylation of SMO and
HHIP were closely linked to colorectal tumors with BRAF
V600E
(Table S3). SMO and HHIP are involved in the regulation of the
Hedgehog (Hh) signaling pathway. It has been demonstrated that
elevated expression of SMO might contribute to colorectal
tumorigenesis through activation of the Wnt signaling pathway
in a mouse model and colorectal cancer cell lines [29]. Notably, it
appeared that the expression of SMO was silenced in colorectal
cancer cell lines harboring BRAF
V600E [29]. Our data in primary
colorectal tumors indicate that the CIMP-specific promoter DNA
hypermethylation may result in a different effect of the Hedgehog
(Hh) signaling pathway on colorectal tumorigenesis (Table S3).
Our data will be a useful resource for future investigations
toward understanding CIMP and the role of aberrant DNA
hypermethylation in colorectal tumorigenesis. The inactivation of
a senescence pathway by IGFBP7 DNA hypermethylation in
CIMP+ tumors may provide a permissive environment for the
acquisition of BRAF
V600E, thus providing a possible explanation
for the link between BRAF
V600E and CIMP in colorectal cancer.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Royal Brisbane Hospital Human
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tee and the University of Southern California. All patients
provided written informed consent for the collection of samples
and subsequent analysis. DNA from these patients was also
analyzed in a previous publication [5].
Cell Culture and Genomic DNA Isolation
Colorectal cancer cell lines were obtained from American Type
Culture Collection (Manassas, VA, USA). COLO 320DM cells
were grown in DMEM supplemented with 10% FBS, 1 mM
glutamine. An empty vector and an HA-tagged BRAF
V600E cDNA
clone (pMEV-HA, pMEV-BRAF-V599E, Biomyx Technology,
San Diego, CA, USA) were transfected into COLO 320DM cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). G418
(Sigma-Aldrich, St. Louis, MO, USA) (1 mg/ml) was added
48 hours after transfection and resistant clones were randomly
isolated and expanded. Stably expressing clones were maintained
in 500 mg/ml of G418. Genomic DNA from each clone was
isolated as previously described [51].
MethyLight Analysis of Five CIMP-Specific Markers in
Colorectal Cancer Cell Lines
Genomic DNA was treated with sodium bisulfite and
subsequently analyzed by MethyLight as previously described
[5,52]. The primer and probe sequences for the MethyLight
reactions were described previously [5]. The results of MethyLight
analyses were scored as PMR (Percent of Methylated Reference)
values as previously defined [5].
Mutation Analysis and MSI Status of Colorectal Cancer
Cell Lines
Primer sequences and PCR conditions for direct sequencing of
BRAF at codon 600 in exon 15 and at codons 12 and 13 of KRAS
in exon 2 were reported previously [13]. The MSI status of each
cell line was based on the Sanger Institute Cancer Genome Project
(http://www.sanger.ac.uk/) and based on a previous study [53].
Western Blot Analysis
Whole cell extracts were prepared from each resistant clone at
the first passage using CelLytic M Cell Lysis Reagent (Sigma-
Aldrich). Equal amounts of protein from whole cell extracts were
separated on gradient (4–20%) polyacrylamide gels (Invitrogen)
and then transferred to polyvinylidene difluoride (PVDF) mem-
branes (Bio-Rad, Hercules, CA, USA). Blots were probed with the
anti-HA antibodies (Roche, Indianapolis, IN, USA) for HA-
BRAF
V600E, anti-phospho-ERK1/2 (Cell Signaling, Beverly, MA,
USA), and anti-ERK1 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) followed by incubation with species specific horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz). Pro-
teins were visualized using SuperSignal West Pico Chemilumines-
cent Substrate (Pierce, Rockford, IL, USA).
Primary Colorectal Tissue Samples
Primary colorectal tissue samples were collected and DNA was
extracted as previously described [5]. A 58 sample set included five
CIMP+ tumors, five CIMP– tumors and 48 randomly selected
tumors, as indicated previously [5]. A 235 sample set included the
same 48 randomly selected samples described above along with an
additional 187 randomly collected tumors described previously
[5]. CIMP status and mutation status of BRAF and KRAS for each
tumor sample was previously determined [5]. BRAF mutations and
KRAS mutations were found in 15% (33/235) and 33% (74/221) of
the colorectal tumor samples, respectively. The KRAS mutation
status of 14 tumor samples was not available. BRAF mutations and
KRAS mutations were mutually exclusive [5].
DNA Methylation Analysis by the Illumina GoldenGate
and Infinium DNA Methylation Platforms
Genomic DNA was bisulfite converted using the EZ-96 DNA
Methylation Kit (ZYMO Research, Orange, CA, USA) according
to manufacturer’s protocol. Illumina GoldenGate DNA methyl-
ation analyses were performed as previously described [16] at the
USC Epigenome Center Core Facility. Target sequences for the
assay and detailed information on each interrogated CpG site and
the associated gene on the ‘‘GoldenGate Methylation Cancer
Panel 1’’ are described at www.illumina.com. The Illumina
Infinium DNA methylation assay was performed following
manufacturer’s specifications. Detailed information on each
interrogated CpG site and the associated gene on the Infinium
BeadArray is available at www.illumina.com.
Identification of CIMP-Associated DNA Methylation
Markers Using 58 Primary Colorectal Tumor Samples
For the hierarchical cluster analysis on 58 primary tumor
samples shown in Figure 3, we used the b-values obtained from
1,421 reactions (84 X-linked reactions were omitted). We used
Euclidian distance and Ward’s linkage method to perform the
clustering (JMP 6.0 software, SAS Institute, Cary, NC, USA). In
order to identify CIMP-associated CpG sites, we performed a t-test
on the difference in the b-value between the CIMP-positive group
(11 tumors) and CIMP-negative group (47 tumors). We selected
100 CpG sites with P,0.001 after a correction for multiple-
comparison [45] and mean |Db|.0.17, the estimated error in b
[16].
Quantitative Real-Time RT-PCR
Total RNA from colorectal cancer cell lines were isolated using
RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). Reverse
transcription reaction was performed using the SuperScriptH III
First-Strand Synthesis kit (Invitrogen). Quantitative real-time PCR
was performed with primers and probe purchased from Applied
Biosystems (Assay ID Hs00266026_m1) (Foster City, CA, USA).
The raw expression values were normalized to those of PCNA.
Supporting Information
Dataset S1 Raw b-values obtained from the Illumina Gold-
enGate DNA methylation assay on 58 primary colorectal tumor
samples. Samples are labeled with internal IDs.
Found at: doi:10.1371/journal.pone.0008357.s001 (1.72 MB
XLS)
Table S1 Characteristics of the 58 Primary colorectal tumor
samples.
Found at: doi:10.1371/journal.pone.0008357.s002 (0.02 MB
XLS)
Table S2 One hundred (100) CpG sites that have significantly
higher levels of DNA methylation in CIMP-positive versus CIMP-
negative tumors. P values and difference in mean b-values between
CIMP-positive tumors and CIMP-negative tumors are also
included.
Found at: doi:10.1371/journal.pone.0008357.s003 (0.02 MB
XLS)
Table S3 The Illumina GoldenGate DNA methylation loci
specifically methylated in colorectal tumors harboring BRAF
V600E.
We performed the Illumina GoldenGate DNA methylation assay
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BRAF mutation status have been determined previously [5]. We
dichotomized the DNA methylation b-value (methylated or
unmethylated) for each locus. The dichotomization threshold
was chosen for each locus using the mean b-value + 3SD (standard
deviations) from ten normal mucosal samples. The table lists 89
Illumina GoldenGate DNA methylation targets (of 60 genes)
selected with P,0.001 (Fisher’s exact test) after Bonferroni
correction for multiple comparisons. Target CpG sites are sorted
based on their P values.
Found at: doi:10.1371/journal.pone.0008357.s004 (0.03 MB
XLS)
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